PURPOSE: Pulmonary Embolism (PE) is a multi factorial disease in which acquired and genetic causes are involved. Statins, in addition to their lipid lowering effect, have many antithrombotic effects. The objective of this study is to evaluate the influence of statins use on the clinical outcome in patients with PE.
METHODS: We retrospectively reviewed the medical records of 129 hospitalized patients for a documented pulmonary embolism from 2003 to 2006, 27 were taking statins and 102 were not. Clinical outcome, defined as treatment with tPA, requirement for intubation and mortality were analyzed among the two groups.
RESULTS: Of all patients, 102 (79%) were not taking statins (39 males, 63 females, age range 21 to 94 years, mean age 56.5 years ) and 27 (21%) were on statins ( 13 males, 14 females, age range 45 to 85 years, mean age 69.4 years ). In the group not taking statins, 11 (11%) required intubation and 6 (6%) received tPA. None of the patients in the statins group was intubated and none of them required treatment with tPA. There were 6 deaths (6%) directly attributed to PE in the non statins group. None died in the statins group. None of these associations was statistically significant (P > 0.05, all cases).
CONCLUSION: Adverse clinical outcome and mortality were higher among patients with pulmonary embolism not receiving statins, but we were not able to detect significant association. This possible protective effect of statins warrants further investigations in a larger sample.
CLINICAL IMPLICATIONS: In addition to its cardiovascular protective effect, statins might have a role in modulating the clinical outcome in patients with PE.
DISCLOSURE: Ashraf Rashid, None.